Author: Andrew Premovich

Meet SIWA Therapeutics, the startup challenging aging, cancer and degenerative diseases. Senescent cells (cells that have stopped dividing due to damage) are causally connected with aging and aging-related diseases, including cancer. “While they don’t divide like cancer cells, senescent cells are highly active metabolically,” explains SIWA co-founder and CEO, Lewis Gruber. “They can poison the tumor micro-environment — inducing, progressing and metastasizing cancer in the cells around them.”  Therefore, Gruber and SIWA developed a monoclonal antibody, SIWA 318H, that is sensitive to a marker appearing on both senescent cells and cancer cells, ultimately binding to the cell, destroying it and removing the debris. “In our first in-vivo study, we successfully removed the senescent cells,” explains SIWA co-founder and Chief Strategy Officer, Misty Gruber. “In the second in-vivo study, we reduced…

SIWA Therapeutics, Inc., a privately held biotechnology company developing a family of monoclonal antibodies to prevent, slow or reverse aging, aging-related and degenerative diseases by reducing senescent cells, announced today that Dr. Thomas Tang has joined its Scientific Advisory Board. Dr. Tang is the CEO of First Dimension BioSciences, a genetic information database company focusing on cancer genomes to establish a statistical compendium of mutation profiles in a state-of-the-art computational data center. He has over 20 years of experience in genomics and bioinformatics research. “Dr. Tang’s addition to the SIWA team will resurrect a productive past partnership,” said Lewis Gruber, co-founder and chief executive officer of SIWA. ‘Tom was one of the early scientists at my first company, Hyseq, Inc. He was a key player in developing Hyseq’s genomics database…

SIWA Therapeutics Takes a Key Step Forward in Novel Efforts to Treat Cancer by Removing Senescent Cells Announces Humanization of Anti-Aging Antibody that Inhibits Tumor Metastasis Chicago, IL, May 18, 2017 – Biotechnology innovator SIWA Therapeutics announced that it has successfully humanized its SIWA 318 monoclonal antibody, a significant milestone in the race to treat cancer and numerous other diseases by removing senescent cells, which become increasingly problematic as humans age. Senescent cells lose their ability to divide or replicate for a variety of reasons and also secrete chemicals which interfere with the normal functions of other cells as well as contribute to inflammation. When too many senescent cells accumulate, they can cause or exacerbate a variety of age-related and degenerative diseases including arthritis, ALS, Alzheimer’s, Parkinson’s, heart disease and…

SIWA Therapeutics Demonstrates Senescent Cell Clearing Antibody Inhibits Tumor Metastasis Chicago IL -- SIWA Therapeutics today reports results of its recent in vivo preclinical study which showed that its monoclonal antibody for removing senescent cells, SIWA 318, significantly inhibited tumor metastasis. Importantly, there were no observable adverse effects from the treatment and no increase in tumor growth over the control group. “These results suggest that the removal of senescent cells may become a therapeutic approach against metastatic cancers,” said Lewis Gruber, co-founder and chief executive officer of SIWA Therapeutics. “Based on data we and the rest of the scientific community have generated over the last several years, the evidence is clearly mounting that senescent cells are causally implicated in the manifestation and progression of many diseases including cancer metastasis.” The study…